Julie Johnson
Director and Principal Investigator, Clinical and Translational Science Institute, Associate Dean for Clinical and Translational Research in the Ohio State College of Medicine, Associate Vice President of Research for The Ohio State University, Dr. Samuel T. and Lois Felts Mercer Professorship of Medicine and Pharmacology and Professor of Medicine and Pharmacy.
Dr. Johnson serves as the director of the Clinical and Translational Science Institute (CTSI) where she is the Principal Investigator of a seven-year $37.9 million Clinical and Translation Science Award from the National Institutes of Health.
A native Ohioan, Dr. Johnson earned her Bachelor of Science in Pharmacy from The Ohio State University, followed by her Doctor of Pharmacy from the University of Texas at Austin and the University of Texas Health Science Center at San Antonio. She returned to Ohio State to complete a postdoctoral fellowship in pharmacokinetics/cardiovascular pharmacology.
Before joining Ohio State, Dr. Johnson served on the faculty at the University of Florida (UF) where she was a Distinguished Professor of Pharmacy and Medicine and became the first female dean of the College of Pharmacy, serving from 2013 to 2022. Under her leadership, the University of Florida College of Pharmacy grew its faculty by 90% and rose from No. 14 to No. 5 in the U.S. News & World Report rankings of the best pharmacy colleges in the nation. The college’s annual research funding also increased from approximately No. 20 to No. 3 among the nation’s top colleges of pharmacy and saw the highest percentage of under-represented, minority students among professional degree programs at the University of Florida. At UF she also served as a department chair, Founding Director of the Center for Pharmacogenomics and Founding Director of the UF Health Precision Medicine Program.
An internationally recognized leader in clinical pharmacology, pharmacogenomics and genomic medicine, Dr. Johnson has an extensive record of clinical and translational research, focusing on cardiovascular pharmacogenomics and the implementation of precision medicine approaches into clinical practice. She has a long record of funding from the National Institutes of Health (NIH) and has secured approximately $55 million in research funding as a PI. She has written more than 330 peer-reviewed original research articles and was named Clarivate Analytics Highly Cited Researcher, an accomplishment held by just 1 in 1,000 scientists globally whose publications rank in the top 1% of citations in the previous decade.
Dr. Johnson has received many notable awards and honors for her work. She was elected to the National Academy of Medicine and is an elected fellow of the American Association for the Advancement of Science, the American Heart Association (AHA), the American College of Clinical Pharmacy and the American College of Clinical Pharmacology. She was the recipient of the Southeastern Universities Research Association Distinguished Scientist Award, the Leon I Goldberg Young Investigator and the Rawls Palmer Progress in Medicine Awards from the American Society for Clinical Pharmacology and Therapeutics (ASCPT). She also holds the Volwiler Research Achievement Award and the Paul Dawson Biotechnology Research Award from the American Association of Colleges of Pharmacy and mentoring awards from the AHA and ASCPT. She has also held numerous service positions, including roles with the NIH, U.S. Food and Drug Administration, Centers for Disease Control and Prevention and the American Heart Association.